{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"title":"TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3"}]}],"title":"SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"}]}],"title":"TEAEs Leading to Dose Modifications"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3"}]}],"title":"TEAEs Leading to Treatment Discontinuation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurred after receiving study drug. An SAE was any untoward medical occurrence or effect that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically important due to other reasons than the above mentioned criteria.","groups":[{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, once daily (QD) for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 20 cycles. Participants with locally advanced or metastatic solid tumors with no standard therapeutic alternative in the United States were included in this cohort.","id":"OG000","title":"Western Safety Cohort"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set included all participants who received any amount of study drug. As pre-specified in the protocol, this outcome measure reports data only in the participants with locally advanced or metastatic solid tumors in the Western Safety Cohort.","reportingStatus":"POSTED","timeFrame":"From first dose of the study drug up to 30 days after the last dose (Up to approximately 15 months)","title":"Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs Leading to Dose Modifications and TEAEs Leading to Treatment Discontinuation in Western Safety Cohort","type":"PRIMARY","unitOfMeasure":"percentage of participants"}